Literature DB >> 34928202

Significant variability exists in the cytotoxicity of global methicillin-resistant Staphylococcus aureus lineages.

Maisem Laabei1, Sharon J Peacock2, Beth Blane2, Sarah L Baines3, Benjamin P Howden3,4, Timothy P Stinear3, Ruth C Massey5.   

Abstract

Staphylococcus aureus is a major human pathogen where the emergence of antibiotic resistant lineages, such as methicillin-resistant S. aureus (MRSA), is a major health concern. While some MRSA lineages are restricted to the healthcare setting, the epidemiology of MRSA is changing globally, with the rise of specific lineages causing disease in healthy people in the community. In the past two decades, community-associated MRSA (CA-MRSA) has emerged as a clinically important and virulent pathogen associated with serious skin and soft-tissue infections (SSTI). These infections are primarily cytotoxin driven, leading to the suggestion that hypervirulent lineages/multi-locus sequence types (STs) exist. To examine this, we compared the cytotoxicity of 475 MRSA isolates representing five major MRSA STs (ST22, ST93, ST8, ST239 and ST36) by employing a monocyte-macrophage THP-1 cell line as a surrogate for measuring gross cytotoxicity. We demonstrate that while certain MRSA STs contain highly toxic isolates, there is such variability within lineages to suggest that this aspect of virulence should not be inferred from the genotype of any given isolate. Furthermore, by interrogating the accessory gene regulator (Agr) sequences in this collection we identified several Agr mutations that were associated with reduced cytotoxicity. Interestingly, the majority of isolates that were attenuated in cytotoxin production contained no mutations in the agr locus, indicating a role of other undefined genes in S. aureus toxin regulation.

Entities:  

Keywords:  Staphylococcus aureus; bacterial pathogenesis; bacterial virulence; cytotoxicity

Mesh:

Substances:

Year:  2021        PMID: 34928202      PMCID: PMC8744995          DOI: 10.1099/mic.0.001119

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


Introduction

is responsible for a wide array of diseases ranging from superficial skin infections to severe, life-threatening cases of pneumonia and bacteraemia [1]. The emergence of antibiotic resistant lineages including methicillin-resistant (MRSA) has complicated treatment. For decades the circulating MRSA lineages appeared to be limited to causing infections within healthcare settings in patients with predisposing conditions who were susceptible to infection [2]. However, in the 1990s distinct MRSA lineages, unrelated to earlier circulating MRSA lineages, started to emerge outside of healthcare settings to cause infections in otherwise healthy individuals [2, 3]. Community-associated MRSA (CA-MRSA) isolates result in similar clinical manifestations, such as severe skin and soft-tissue infections (SSTIs), despite broad genetic diversity among CA-MRSA lineages [4]. Understanding the differences between the healthcare restricted MRSA lineages and the more recently emerged CA-MRSA lineages has been the focus of much attention [3]. Molecular and epidemiological studies of CA-MRSA isolates have identified multiple putative virulence factors, namely toxins, associated with the hypervirulent phenotype characteristic of CA-MRSA isolates. The majority of CA-MRSA isolates harbour lukSF-PV which encodes the bi-component pore-forming leucocidin [4]. Human neutrophils have been shown to be highly susceptible to PVL-mediated lysis due to the expression of complement receptors, C5aR and C5L2, which are required for PVL binding [5]. Importantly, the role of PVL in pathogenesis is likely dependent on the site of infection; a clear role is observed in a rabbit necrotizing pneumonia model [6], but the role of this toxin in dermonecrosis is less evident [7, 8]. Aside from PVL, over-expression of core genome virulence determinants, notably α-haemolysin (Hla) and α-type phenol-soluble modulins (α-PSMs), has been hypothesised to significantly contribute to the enhanced virulence of CA-MRSA isolates [9-12]. Hla is the prototypical β-barrel pore-forming cytotoxin [13]. Multiple studies utilising serological and animal models of infection have indicated a prominent role for Hla in the pathogenesis of disease [14]. The α-PSMs are characterised as small amphipathic α-helical peptides that efficiently lyse numerous cell types, independent of cell specific receptor [11, 15]. As with Hla, α-PSMs significantly contribute to virulence in a murine infection models of bacteraemia and skin lesions [11]. Toxin regulation in is governed primarily by the accessory gene regulator (agr), which employs a cell density dependent, quorum sensing system to upregulate a suite of secreted virulence factors such as toxins and downregulate surface binding proteins [16]. Accordingly, the agr system plays a central role in the development of a range of infections, most notably in CA-MRSA skin infections [17]. Furthermore, transcriptomic data indicate enhanced agr regulation of important toxins (PVL, Hla and α-PSM), which are frequently associated with CA-MRSA virulence [17]. Together, these studies have contributed to the frequent use of the term ‘hypervirulent’ when referring to CA-MRSA lineages. Recently, studies of toxicity at a population level have reported that this phenotype varies widely within individual MRSA multi-locus sequence types (STs) [18], suggesting that the virulence of an individual MRSA isolate should not be inferred from its genotype [18]. Non-cytolytic clinical isolates are commonly referred to as ‘Agr dysfunctional’, due to the frequency at which mutations occur within the sensor kinase (AgrC) or response regulator (AgrA) encoding genes, impacting significantly on toxin expression. To examine this in greater detail, and across a globally representative collection of isolates, we focussed on a collection of 475 MRSA isolates representing five major MRSA STs (ST22, ST93, ST8, ST239 and ST36; Table S1, available in the online version of this article for further details) collected from Europe, North and South America, Asia and Australia, and examined their toxicity based on their ability to lyse human cells. As no single cell line exists that is susceptible to all of the toxins secreted by , we use the THP-1 monocyte-macrophage cell line, which based on our empirical evidence, is susceptible to the widest range of toxins, expressing receptors for PVL [5] and Hla [19] and susceptible to δ-haemolysin and α-PSMs [20]. Our findings indicate that toxicity varies significantly within STs and therefore lineage should not be used as a metric to infer pathogenicity. In addition, we have identified novel Agr mutations associated with attenuated toxicity and confirm that multiple isolates with reduced cytotoxicity have no mutations within the Agr operon, indicating the existence of other undefined toxin regulating genes in .

Methods

Bacterial isolates and growth conditions

A list of the MRSA clinical isolates used in this study can be found in Table S1. isolates were grown overnight in 5 ml of Tryptic-Soy Broth (TSB; Sigma) in a 30 ml glass tube at 37 °C with shaking at 180 r.p.m. Overnight cultures were used to inoculate 5 ml of fresh TSB at a dilution of 1 : 1000 and incubated for 18 h at 37 °C with shaking at 180 r.p.m. Under these growth conditions all clinical isolates reached an OD600nm within the range of 4.5–5.5 after 18 h growth. toxin containing supernatants were harvested from 18 h cultures by centrifugation at 14600 r.p.m. for 10 min. All clinical isolates have been genome-sequenced as described previously [18, 20–24]. Paired-end reads for these isolates were mapped to the following reference isolates: ST22 (HO 50960412 [24]), ST93 (JKD6159 [21, 22]), ST8 (USA300 strain LAC [20]), ST239 (TW20 [18, 23]) and ST36 (MRSA252 [24]). Data have been deposited in the European Nucleotide Archive under the following accession numbers ST239 (ERP000228 and ERA000102), ST22 and ST36 (ERP000871), ST93 (SRA026511.1) and ST8 (PRJEB2870).

THP-1 cell culture

THP-1 monocyte-macrophage cell line (ATCC#TIB-202) was routinely grown in suspension in 30 ml of RPMI-1640 medium (Gibco: 11340892), supplemented with 10 % heat-inactivated foetal bovine serum (FBS) (Sigma: F7524), 1 µM l-glutamine, 200 units ml−1 penicillin and 0.1 mg ml−1 streptomycin (Sigma: G6784) at 37 °C in a humidified incubator with 5 % CO2. THP-1 cells were routinely viewed microscopically and sub-cultured every 3–4 days. For use in cytotoxicity assays, cells were collected by centrifugation at 1000 r.p.m. for 5 min at room temperature and resuspended to a final density of 1–1.2×106 cells ml−1 in tissue grade phosphate buffered saline (Gibco). Cell viability was analysed using the Guava ViaCount reagent (Luminex) and easyCyte flow cytometry, typically yielding >95 % viability following THP-1 collection.

Cytotoxicity assay

The cytotoxicity assay was optimised previously [20]. Briefly, to evaluate toxicity, 20 µl of harvested supernatant (either used as 100 % or diluted to 70%, 30 % or 10 % in TSB) was incubated with 20 µl of washed THP-1 cells for 12 min at 37 °C under static conditions. Cell death was quantified using the Guava ViaCount reagent and easyCyte flow cytometry according to manufacturer’s instructions. The toxicity of each isolate was measured with two technical repeats and three biological repeats with error bars indicating the standard deviation (SD). LAC (a highly toxic CA-MRSA isolate) supernatant and TS broth were used as positive and negative controls, respectively.

Statistical analysis

A one-way ANOVA with Tukey’s multiple comparison test was used to examine differences between experimental results (GraphPad Prism v9.0), where a P value<0.05 was considered to be statistically significant.

Results and discussion

S. aureus cytotoxicity is highly variable both between and within sequence types

In this study we compared the cytotoxicity profiles of previously published collections of MRSA isolates (i.e. sequence type (ST) 8 [20], ST22 and ST36 [24]; n=330) with newly derived toxicity profiles (ST93 and ST239; n=145) to provide a comprehensive and globally distributed picture of toxin expression by . What was immediately apparent was that the individual STs contained numerous isolates that were either extremely toxic (100 % cell death) or non-toxic (0 % cell death), and could not be reliably assayed under the same conditions. As a result, we used the supernatant of two of the STs (ST239 and ST36) undiluted (100%) and for the other three STs (ST22, ST93 and ST8) we diluted them to 30 % (vol/vol) in TSB (Fig. 1). The cytotoxicity of each isolate was measured using three biological repeats with high reproducibility (Fig. S1). The proportion of ST239 and ST36 isolates that killed more than 50 % of the THP-1 cells was 44 and 39 %, respectively. By contrast, the proportion of ST8, ST22 and ST93 isolates that killed more than 50 % of cells was 87, 84 and 85 %, respectively. Given both the difference in the proportion of isolates killing more than 50 % of the cells and the differences in dilutions required (100 vs 30 %), this demonstrates that ST8, ST22 and ST93 contain a higher proportion of highly toxic isolates than ST239 and ST36. When comparing the median difference in cytotoxicity between STs, we observe that ST22 are significantly more cytotoxic than ST8 isolates (P=0.025). However, no difference in cytotoxicity is observed between ST22 and ST93, ST93 and ST8 or ST239 and ST36. However, what was equally striking from this initial analysis is the scale of the variation in the toxicity of the isolates within each ST (Fig. 1).
Fig. 1.

Variation in cytotoxicity between and within MRSA sequence types. The cytotoxicity of each isolate from five MRSA STs (ST22 (n=110), ST93 (n=58), ST8 (n=134), ST239 (n=87) and ST36 (n=86)) was quantified by incubating cell-free supernatant (either diluted to 30 % using sterile TS broth or used undiluted (100%)) with cultured THP-1 cells and cytotoxicity examined by flow cytometry. The cytotoxicity of each isolate was quantified using three biological repeats with a single dot representing the mean value for each isolate and the median of each sequence type indicated by the horizontal bars.

Variation in cytotoxicity between and within MRSA sequence types. The cytotoxicity of each isolate from five MRSA STs (ST22 (n=110), ST93 (n=58), ST8 (n=134), ST239 (n=87) and ST36 (n=86)) was quantified by incubating cell-free supernatant (either diluted to 30 % using sterile TS broth or used undiluted (100%)) with cultured THP-1 cells and cytotoxicity examined by flow cytometry. The cytotoxicity of each isolate was quantified using three biological repeats with a single dot representing the mean value for each isolate and the median of each sequence type indicated by the horizontal bars.

Toxicity cannot be inferred solely from the MRSA sequence type

To further compare the toxicity between STs we took the five most and five least toxic isolates from each MRSA ST and quantified their cytotoxicity over a range of dilutions of their supernatant (Fig. 2). The cytotoxicity of each supernatant dilution was measured using three biological repeats with high reproducibility (Fig. S2). The mean cytotoxicity of the five least toxic ST8 isolates was slightly higher than those from the other STs, but this was not statistically significant (P>0.05, Fig. 2a). This demonstrates that each of the five MRSA STs contain isolates expressing comparable low levels of cytotoxicity. Of the most toxic isolates, there were significant differences in cytotoxicity across the five STs (Figs 2 and S2). At a supernatant dilution of 10 % the ST22 and ST8 isolates were on average more toxic than the others (P<0.05 for each comparison, Fig. 2b). At supernatant dilution of 30%, the ST22, ST93 and ST8 were on average more toxic than the other STs (P<0.05 for each comparison values), while at dilution 70%, the ST36 isolates were statistically significantly less toxic than the other STs (P<0.05 for each comparison values).
Fig. 2.

Cytotoxicity of the least and highest toxic isolates from each of the five MRSA sequence type. The supernatant of the five least (a) and highest (b) toxic isolates from each sequence type was diluted to 10, 30, or 70 % supernatant in sterile TS broth or used undiluted (100%) and the percentage cell death of THP-1 cells examined. The cytotoxicity of each isolate was quantified using three biological repeats and the data is presented as the mean and standard deviation across the five isolates.

Cytotoxicity of the least and highest toxic isolates from each of the five MRSA sequence type. The supernatant of the five least (a) and highest (b) toxic isolates from each sequence type was diluted to 10, 30, or 70 % supernatant in sterile TS broth or used undiluted (100%) and the percentage cell death of THP-1 cells examined. The cytotoxicity of each isolate was quantified using three biological repeats and the data is presented as the mean and standard deviation across the five isolates. ST22, ST93 and ST8 all contain the community-associated Type IV SCCmec element, which prior to this study would have led to them being referred to as hypervirulent [9, 25]. By comparison, ST239 and ST36 isolates contain the type III and II healthcare-associated SCCmec elements, respectively. While the ST8 and ST22 collections did contain the most toxic isolates, the most toxic ST93 isolates were no more toxic than those from the ST239 collection but was statistically more cytotoxic than the most toxic isolates of ST36 when compared at 70 % dilution (ST93 vs ST36 P=0.043) and at 30 % dilution (P=0.017). (Figs 2b and S2b). This may be a result of differential expression of cytotoxins to which our cell line is not susceptible. However, the ST93 collection did contain a higher proportion of highly toxic isolates than the ST239 and ST36 collections, which is what we observed with the other type IV SCCmec carrying MRSA STs studied here (Fig. 1). This observation aligns with earlier work demonstrating that the type IV element has less of a down-regulating effect on toxicity compared to the larger hospital associated SCCmec types [26].

Agr mutations alone do not explain all low toxic isolates

To understand the molecular mechanisms behind the observed variation in cytotoxin production, we sought to examine the impact of sequence variability within the Agr regulatory locus on this phenotype. AgrC and AgrA represent the sensor kinase and response regulator of the Agr system, respectively (Fig. 3a), and mutations within the genes encoding these key proteins are frequently associated with reduced toxin production by clinical isolates (Fig. 3a) [16]. As the genome sequences were available for all the isolates studied here, we interrogated these and found that of the 475 isolates, 14 isolates had non-synonymous mutations in agrA (Table 1) and 35 isolates had non-synonymous mutations in agrC (Table 2). The location of each of the amino acid changes inferred by these mutations is indicated in Tables 1 and 2 and have been mapped onto a representation of each protein (AgrA, Fig. 3b; AgrC, Fig. 3c) where the critically active regions are indicated.
Fig. 3.

Accessory gene regulatory (Agr) system of labelled with amino acid substitutions associated with reduced cytotoxicity. (a) The Agr locus consists of two divergent transcripts driven by the P2 and P3 promoters. P2 drives the expression of the quorum sensing systems consisting of the signal synthesis (agrBD) and signal detection (agrAC) genes. AgrB and AgrD cooperative to process and secrete autoinducing peptides (AIPs) which are sensed by the polytopic transmembrane protein, AgrC. AgrCA function as a two-component signal transduction system with AgrC phosphorylating AgrA resulting in a conformational change promoting DNA binding to the intergenic region between P2 and P3 driving their expression. The effector molecule of the Agr system, RNAIII, is expressed from P3 resulting in a shift in virulence gene expression, namely enhanced cytolytic toxin expression. (b) The C-terminal DNA binding domain of AgrA is shown as a ten-stranded elongated β-β-β sandwich, where the β-strands are shown in blue, helices shown in orange and loop regions shown in grey. Mutation associated with reduced toxicity are highlighted in the specific regions of the protein in which they occur. (c) The transmembrane sensor and cytoplasmic histidine kinase domains of AgrC are highlighted. The central histidine residue (H239) within the H-box of the DHp subdomain and the CA subdomain N-box asparagine (N339) and glycine residues of the G box (G394 and G396) are indicated. Residues labelled in red have been identified in this study to be associated with reduced cytotoxicity.

Table 1.

Comparison of mutations and amino acid substitutions (AA-sub) identified in the accessory gene regulator A (agrA) gene and cytotoxicity of MRSA isolates

ST/Strain ID

Mutation / AA-sub

Description

Cell death (%)

ST22

ASARM205

Y95H

Unknown

45

ASARM93

E163G

Glutamic residue lies within beta-sheet 3, important in beta-beta-beta sandwich formation, involved in salt bridge formation

9

ASARM207

K223Stop

Dysfunctional, truncated AgrA

5

ASARM128

K236Stop

Dysfunctional, truncated AgrA

3

ST93

Sa_TPS3105

Frameshift I156, T178

Dysfunctional, truncated AgrA

6

ST8

MR026

(-t)2 149 463

Dysfunctional, frameshift and predicted premature stop codon at 173

12

ST239

AGT9

A47D

Unknown

6

MAL119

S139I

Functional

91

ST30

EOE120

D157Y

Important in formation of elongated beta-beta-beta fold and salt bridge formation

4

ASARM63

H169Y

Dysfunctional, His residue is essential for DNA binding

5

EOE176

Q179Stop codon

Dysfunctional, truncated AgrA

5

EOE161

Q179Stop codon

Dysfunctional, truncated AgrA

5

EOE171

Q179Stop codon

Dysfunctional, truncated AgrA

5

EOE169

Q179Stop codon

Dysfunctional, truncated AgrA

6

Table 2.

Comparison of mutations and amino acid substitutions (AA-sub) identified in the accessory gene regulator C (agrC) gene and cytotoxicity of MRSA isolates

ST/Strain ID

Mutation / AA-sub

Description

Cell death (%)

ST22

ASARM204

S47T and V367I

Mutation in extracellular loop; mutation in cytoplasmic c-terminal domain

5

ASARM84

M53I

Unknown; mutation in membrane spanning region

5

ASARM224

A57V

Functional

91

ASARM217

A57V

Functional

92

ASARM208

A57V

Functional

97

ASARM61

A57V

Functional

97

ASARM200

Y121H and Q202H

Functional

92

ASARM201

Y121H and Q202H

Functional

93

ASARM154

F162V

Unknown; mutation in membrane spanning region

13

ASARM97

A340V

Mutation of highly conserved residue in N-box CA kinase subdomain

14

ST93

Sa_TPS3155

Y71H

Unknown; mutation in membrane spanning region

42

Sa_TPS3165

F162S

Unknown; mutation in membrane spanning region

15

Sa_TPS3167

M20I

Unknown; mutation in membrane spanning region

56

Sa_TPS3148

R235C

Mutation of conserved residue in H-box in DHp subdomain

6

Sa_TPS3151

D240N

Mutation of conserved residue in H-box in DHp subdomain

12

Sa_TPS3161

G284D

Mutation in histidine kinase domain -predicted to be dysfunctional

9

ST8

MR030

(-t)2 146 811

Deletion (-t;2146811) within intergenic region between P2/P3 agr promoter

64

MR081

(-t)2 146 811

Deletion (-t;2146811) within intergenic region between P2/P3 agr promoter

23

MR083

(-t)2 146 811

Deletion (-t;2146811) within intergenic region between P2/P3 agr promoter

65

USFL093

Y32T

Functional

95

MR065

L381F

Mutation of non-conserved residue in G-box CA kinase subdomain

35

ST239

GRE4

T246M

Mutation of conserved residue in H-box in DHp subdomain

5

ICP5062

T247I

Mutation of conserved residue in H-box in DHp subdomain

6

HU5

I311T; A343T

Dysfunctional; I311T/A343T resulted in delayed RNAIII activity

15

HU11

I311T; A343T

Dysfunctional; I311T/A343T resulted in delayed RNAIII activity

18

DEU29

I311T; A343T

Dysfunctional; I311T/A343T resulted in delayed RNAIII activity

19

DEU37

I311T; A343T

Dysfunctional; I311T/A343T resulted in delayed RNAIII activity

19

HU6

I311T; A343T

Dysfunctional; I311T/A343T resulted in delayed RNAIII activity

120

DEU20

I311T; A343T

Dysfunctional; I311T/A343T resulted in delayed RNAIII activity

21

DEU9

I311T; A343T

Dysfunctional; I311T/A343T resulted in delayed RNAIII activity

20

DEU17

I311T; A343T

Dysfunctional; I311T/A343T resulted in delayed RNAIII activity

16

HU16

I311T; A343T

Dysfunctional; I311T/A343T resulted in delayed RNAIII activity

18

CHI61

M326T

Functional

80

ST36

EOE173

T247I

Mutation of conserved residue in H-box in DHp subdomain

6

EOE096

T388I

Mutation of conserved residue in G-box CA subdomain

7

Accessory gene regulatory (Agr) system of labelled with amino acid substitutions associated with reduced cytotoxicity. (a) The Agr locus consists of two divergent transcripts driven by the P2 and P3 promoters. P2 drives the expression of the quorum sensing systems consisting of the signal synthesis (agrBD) and signal detection (agrAC) genes. AgrB and AgrD cooperative to process and secrete autoinducing peptides (AIPs) which are sensed by the polytopic transmembrane protein, AgrC. AgrCA function as a two-component signal transduction system with AgrC phosphorylating AgrA resulting in a conformational change promoting DNA binding to the intergenic region between P2 and P3 driving their expression. The effector molecule of the Agr system, RNAIII, is expressed from P3 resulting in a shift in virulence gene expression, namely enhanced cytolytic toxin expression. (b) The C-terminal DNA binding domain of AgrA is shown as a ten-stranded elongated β-β-β sandwich, where the β-strands are shown in blue, helices shown in orange and loop regions shown in grey. Mutation associated with reduced toxicity are highlighted in the specific regions of the protein in which they occur. (c) The transmembrane sensor and cytoplasmic histidine kinase domains of AgrC are highlighted. The central histidine residue (H239) within the H-box of the DHp subdomain and the CA subdomain N-box asparagine (N339) and glycine residues of the G box (G394 and G396) are indicated. Residues labelled in red have been identified in this study to be associated with reduced cytotoxicity. Comparison of mutations and amino acid substitutions (AA-sub) identified in the accessory gene regulator A (agrA) gene and cytotoxicity of MRSA isolates ST/Strain ID Mutation / AA-sub Description Cell death (%) ST22 ASARM205 Y95H Unknown 45 ASARM93 E163G Glutamic residue lies within beta-sheet 3, important in beta-beta-beta sandwich formation, involved in salt bridge formation 9 ASARM207 K223Stop Dysfunctional, truncated AgrA 5 ASARM128 K236Stop Dysfunctional, truncated AgrA 3 ST93 Sa_TPS3105 Frameshift I156, T178 Dysfunctional, truncated AgrA 6 ST8 MR026 (-t)2 149 463 Dysfunctional, frameshift and predicted premature stop codon at 173 12 ST239 AGT9 A47D Unknown 6 MAL119 S139I Functional 91 ST30 EOE120 D157Y Important in formation of elongated beta-beta-beta fold and salt bridge formation 4 ASARM63 H169Y Dysfunctional, His residue is essential for DNA binding 5 EOE176 Q179Stop codon Dysfunctional, truncated AgrA 5 EOE161 Q179Stop codon Dysfunctional, truncated AgrA 5 EOE171 Q179Stop codon Dysfunctional, truncated AgrA 5 EOE169 Q179Stop codon Dysfunctional, truncated AgrA 6 Comparison of mutations and amino acid substitutions (AA-sub) identified in the accessory gene regulator C (agrC) gene and cytotoxicity of MRSA isolates ST/Strain ID Mutation / AA-sub Description Cell death (%) ST22 ASARM204 S47T and V367I Mutation in extracellular loop; mutation in cytoplasmic c-terminal domain 5 ASARM84 M53I Unknown; mutation in membrane spanning region 5 ASARM224 A57V Functional 91 ASARM217 A57V Functional 92 ASARM208 A57V Functional 97 ASARM61 A57V Functional 97 ASARM200 Y121H and Q202H Functional 92 ASARM201 Y121H and Q202H Functional 93 ASARM154 F162V Unknown; mutation in membrane spanning region 13 ASARM97 A340V Mutation of highly conserved residue in N-box CA kinase subdomain 14 ST93 Sa_TPS3155 Y71H Unknown; mutation in membrane spanning region 42 Sa_TPS3165 F162S Unknown; mutation in membrane spanning region 15 Sa_TPS3167 M20I Unknown; mutation in membrane spanning region 56 Sa_TPS3148 R235C Mutation of conserved residue in H-box in DHp subdomain 6 Sa_TPS3151 D240N Mutation of conserved residue in H-box in DHp subdomain 12 Sa_TPS3161 G284D Mutation in histidine kinase domain -predicted to be dysfunctional 9 ST8 MR030 (-t)2 146 811 Deletion (-t;2146811) within intergenic region between P2/P3 agr promoter 64 MR081 (-t)2 146 811 Deletion (-t;2146811) within intergenic region between P2/P3 agr promoter 23 MR083 (-t)2 146 811 Deletion (-t;2146811) within intergenic region between P2/P3 agr promoter 65 USFL093 Y32T Functional 95 MR065 L381F Mutation of non-conserved residue in G-box CA kinase subdomain 35 ST239 GRE4 T246M Mutation of conserved residue in H-box in DHp subdomain 5 ICP5062 T247I Mutation of conserved residue in H-box in DHp subdomain 6 HU5 I311T; A343T Dysfunctional; I311T/A343T resulted in delayed RNAIII activity 15 HU11 I311T; A343T Dysfunctional; I311T/A343T resulted in delayed RNAIII activity 18 DEU29 I311T; A343T Dysfunctional; I311T/A343T resulted in delayed RNAIII activity 19 DEU37 I311T; A343T Dysfunctional; I311T/A343T resulted in delayed RNAIII activity 19 HU6 I311T; A343T Dysfunctional; I311T/A343T resulted in delayed RNAIII activity 120 DEU20 I311T; A343T Dysfunctional; I311T/A343T resulted in delayed RNAIII activity 21 DEU9 I311T; A343T Dysfunctional; I311T/A343T resulted in delayed RNAIII activity 20 DEU17 I311T; A343T Dysfunctional; I311T/A343T resulted in delayed RNAIII activity 16 HU16 I311T; A343T Dysfunctional; I311T/A343T resulted in delayed RNAIII activity 18 CHI61 M326T Functional 80 ST36 EOE173 T247I Mutation of conserved residue in H-box in DHp subdomain 6 EOE096 T388I Mutation of conserved residue in G-box CA subdomain 7 Given the major role the Agr system plays in regulating cytotoxin production in we examined what proportion of low toxic isolates could be explained by these Agr mutations. We set an arbitrary threshold where we considered any isolate that killed less than 20 % of the cells as ‘low toxicity’, and any that killed more than 80 % as ‘high toxicity’. Of the 475 isolates, 17.7 % (n=84) of the isolates were categorised as low toxicity and of these 34 (40.5 %) had non-synonymous mutations in the agr locus. While of the high toxicity isolates (n=215 (45.2 %)) eight had non-synonymous mutations in the agr locus, suggesting that these amino acids are not critical to the activity of the Agr system (Tables 1 and 2). Of the 34 low toxicity isolates with mutations in the Agr locus, while we cannot assume these mutations are causative without making a series of isogenic mutants, having mapped them to the functional regions of the proteins (Fig. 3b, c) we can hypothesise those mutations that are likely to be causative of the low toxicity phenotype.

Assessment of agrA mutations

The AgrA protein is part of the LytR family of DNA-binding response regulators that modulate virulence determinants in several pathogenic bacteria [27]. This transcription factor contains the LytTR domain which binds with high affinity to both P2 and P3 promoter regions of the agr locus upregulating toxin production (Fig. 3a) [16, 28]. The structure of the C-terminal LytTR DNA binding domain of AgrA (residues 137–238) in complex with a DNA duplex has been solved [29], highlighting the formation of an intricate ten-stranded elongated β-β-β sandwich (Fig. 3b). Key residues within three loop regions extending from the β-sheets makes contact with the major and intervening minor groove of its DNA target resulting in increased transcription from the P2 and P3 promoters and activation of the Agr system [29]. The mutations in eight of the low toxicity isolates resulted in premature truncation of the AgrA protein, which caused a loss of a functional region, and as such can be considered causative of the low toxicity phenotype (Table 1, Fig. 3b). Two of the other low toxicity isolates (ASARM93 and EOE120) had substitution mutations (E163G and D157Y, respectively) within the critical β-β-β sandwich. Mutation E163G occurs within β-strand three which forms the centre of the LytTR domain and plays a role in salt-bridge formation with H174 [29]. Mutation D157Y is located within an α-helix between strands β2 and β3 and forms a salt bridge interaction with both H208 located on helix between β5 and β6 and E141 positioned on the beginning of strand β1. These salt bridge interactions stabilise the LytTR β-β-β fold, and our data indicates that mutations within these residues impairs Agr activity and results in reduced toxicity. Lastly, isolate ASARM63 had a mutation conferring a H169Y change, which results in the loss of a histidine residue critical to the DNA binding activity of AgrA [32]. Only one low toxic agrA mutant contained a substitution in a region with no ascribed function, and that was AGT9 which had an A47D change (not shown in Fig. 3b).

Assessment of agrC mutations

The AgrC protein is composed of a highly variable polytopic transmembrane sensor which relays auto-inducing peptide (AIP) mediated signals to the highly conserved cytoplasmic histidine kinase (HK) domain (Fig. 3a, c) [30]. The AgrC HK domain is composed of two subdomains; the catalytic ATP-binding (CA) domain which promotes the autophosphorylation of the central histidine (His239) residue within the H-box of the dimerized histidine phosphotransfer (DHp) domain (Fig. 3c) [30-32]. The CA subdomain N-box asparagine (N339) and glycine residues situated within the G-box (G394 and G396) are considered essential for ATP binding and Agr activity [33, 34]. Importantly, alanine 340 and threonine 388 are conserved residues within this subdomain [32]. Two low toxic isolates (ASARM97 (A340V) and EOE096 (T388I)) contain substitutions in the CA kinase subdomain region of AgrC, and as such may be causative of the low toxic phenotype. Six low toxic isolates (Sa_TPS3148, Sa_TPS3151, Sa_TPS3161, GRE4, ICP5062 and EOE173) occur in conserved residues within the H-box of the DHp subdomain and as such, are likely to be causative of the low toxicity phenotype. Nine isolates, all ST239 belonging to the Turkish lineage [35], contained a double substitution of I311T and A343T, and in previous work we have functionally verified that these mutations result in a significant delay to RNAIII activation [18]. Molecular modelling has previously indicated that these mutations prevent AgrC dimerization and access to the ATP-binding pocket required for Agr activity which explains the low toxic phenotype [36]. Of the low toxic isolates with agrC mutations, four (ASARM204, ASARM84, ASARM154 and Sa_TPS3165) contain substitutions within either the extracellular or cytoplasmic regions of the protein with no ascribed function, and so we cannot claim with a level of confidence that these are causative of the low toxic phenotype. This study adds to the growing literature indicating that cytotoxin regulation is highly complex in and confirms that there are still undiscovered mechanisms at play that modulate this major virulence phenotype. This works reinforces the importance of Agr mutations in toxicity. The data generated here provides a clearer understanding of the relationship between Agr mutations and toxicity, which may be exploited for future anti-virulence drug design. However, considering that close to 60 % of low toxicity isolates had no Agr mutations demonstrates that numerous regulatory mechanisms await discovery, and work dedicated to unravelling the regulatory circuits controlling the toxicity of is ongoing. This also suggests that use of the term ‘Agr dysfunction’ should be used with consideration of the fact that for many of low toxicity clinical isolates the Agr system is likely to be functional. What this work primarily highlights is the care and consideration needed when inferring terms like ‘hypervirulence’ to an isolate based on its sequence type. There can be no doubt that CA-MRSA lineages have recently emerged and are highly successful. Whether this is a result of ‘hypervirulence’ as opposed to an enhanced ability to transmit amongst otherwise healthy individuals needs further investigation. From the perspective of cytolytic toxin production by MRSA, the level of variability is significant and likely to play a major role in the outcome of disease. Click here for additional data file.
  36 in total

Review 1.  Autoinduction and signal transduction in the regulation of staphylococcal virulence.

Authors:  Richard P Novick
Journal:  Mol Microbiol       Date:  2003-06       Impact factor: 3.501

2.  Structure of the Staphylococcus aureus AgrA LytTR domain bound to DNA reveals a beta fold with an unusual mode of binding.

Authors:  David J Sidote; Christopher M Barbieri; Ti Wu; Ann M Stock
Journal:  Structure       Date:  2008-05       Impact factor: 5.006

Review 3.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

4.  Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury.

Authors:  Binh An Diep; Liana Chan; Pierre Tattevin; Osamu Kajikawa; Thomas R Martin; Li Basuino; Thuy T Mai; Helene Marbach; Kevin R Braughton; Adeline R Whitney; Donald J Gardner; Xuemo Fan; Ching W Tseng; George Y Liu; Cedric Badiou; Jerome Etienne; Gerard Lina; Michael A Matthay; Frank R DeLeo; Henry F Chambers
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

5.  Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection.

Authors:  Scott D Kobayashi; Natalia Malachowa; Adeline R Whitney; Kevin R Braughton; Donald J Gardner; Dan Long; Juliane Bubeck Wardenburg; Olaf Schneewind; Michael Otto; Frank R Deleo
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

6.  Active site mutations in CheA, the signal-transducing protein kinase of the chemotaxis system in Escherichia coli.

Authors:  A Hirschman; M Boukhvalova; R VanBruggen; A J Wolfe; R C Stewart
Journal:  Biochemistry       Date:  2001-11-20       Impact factor: 3.162

7.  Evolution of MRSA during hospital transmission and intercontinental spread.

Authors:  Simon R Harris; Edward J Feil; Matthew T G Holden; Michael A Quail; Emma K Nickerson; Narisara Chantratita; Susana Gardete; Ana Tavares; Nick Day; Jodi A Lindsay; Jonathan D Edgeworth; Hermínia de Lencastre; Julian Parkhill; Sharon J Peacock; Stephen D Bentley
Journal:  Science       Date:  2010-01-22       Impact factor: 47.728

8.  Methicillin resistance reduces the virulence of healthcare-associated methicillin-resistant Staphylococcus aureus by interfering with the agr quorum sensing system.

Authors:  Justine K Rudkin; Andrew M Edwards; Maria G Bowden; Eric L Brown; Clarissa Pozzi; Elaine M Waters; Weng C Chan; Paul Williams; James P O'Gara; Ruth C Massey
Journal:  J Infect Dis       Date:  2012-02-01       Impact factor: 5.226

Review 9.  The changing epidemiology of Staphylococcus aureus?

Authors:  H F Chambers
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

10.  Evolutionary Trade-Offs Underlie the Multi-faceted Virulence of Staphylococcus aureus.

Authors:  Maisem Laabei; Anne-Catrin Uhlemann; Franklin D Lowy; Eloise D Austin; Maho Yokoyama; Khadija Ouadi; Edward Feil; Harry A Thorpe; Barnabas Williams; Mark Perkins; Sharon J Peacock; Stephen R Clarke; Janina Dordel; Matthew Holden; Antonina A Votintseva; Rory Bowden; Derrick W Crook; Bernadette C Young; Daniel J Wilson; Mario Recker; Ruth C Massey
Journal:  PLoS Biol       Date:  2015-09-02       Impact factor: 8.029

View more
  3 in total

1.  Novel method for detecting complement C3 deposition on Staphylococcus aureus.

Authors:  Toska Wonfor; Shuxian Li; Rhys W Dunphy; Alex Macpherson; Jean van den Elsen; Maisem Laabei
Journal:  Sci Rep       Date:  2022-09-21       Impact factor: 4.996

2.  Genomic characterization of two community-acquired methicillin-resistant Staphylococcus aureus with novel sequence types in Kenya.

Authors:  John Njenga; Justin Nyasinga; Zubair Munshi; Angela Muraya; Geoffrey Omuse; Caroline Ngugi; Gunturu Revathi
Journal:  Front Med (Lausanne)       Date:  2022-09-26

3.  Species-Wide Phylogenomics of the Staphylococcus aureus Agr Operon Revealed Convergent Evolution of Frameshift Mutations.

Authors:  Vishnu Raghuram; Ashley M Alexander; Hui Qi Loo; Robert A Petit; Joanna B Goldberg; Timothy D Read
Journal:  Microbiol Spectr       Date:  2022-01-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.